Ani Pharmaceuticals Inc (ANIP) financials
Ani Pharmaceuticals revenue and earnings by year
Ani Pharmaceuticals's revenue was $883 million in the fiscal year to December 31, 2025, up 43.8% from the year before. Net income was $78.3 million, 8.9% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 23.9% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 883 | 614 | 487 | 316 | 216 | 208 | 207 | 202 | 177 | 129 |
| Revenue growth | 43.8% | 26.2% | 53.9% | 46.4% | 3.7% | 0.9% | 2.5% | 14.0% | 37.5% | — |
| Gross profit | 542 | 364 | 305 | 178 | 116 | 121 | 143 | 129 | 98 | 80 |
| Gross margin | 61.4% | 59.3% | 62.7% | 56.1% | 53.5% | 58.2% | 69.4% | 63.8% | 55.3% | 62.1% |
| Operating income | 82 | -4 | 48 | -31 | -44 | -17 | 16 | 35 | 28 | 20 |
| Operating margin | 9.3% | -0.7% | 9.9% | -9.8% | -20.2% | -7.9% | 7.8% | 17.3% | 16.1% | 15.6% |
| Net income | 78 | -19 | 19 | -48 | -43 | -23 | 6 | 15 | -1 | 4 |
| Net margin | 8.9% | -3.0% | 3.9% | -15.1% | -19.7% | -10.8% | 3.0% | 7.7% | -0.6% | 3.1% |
| Diluted EPS | $3.32 | -$1.04 | $0.85 | -$3.05 | -$3.40 | -$1.88 | $0.48 | $1.30 | -$0.10 | $0.35 |
| Free cash flow | 171 | 61 | 110 | -39 | 3 | 9 | 39 | 61 | 29 | 23 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open ANIP in Markets.
How Ani Pharmaceuticals makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Rare Disease & Brands | $165M | 62.2% |
| Generics & Other | $101M | 37.8% |
See also: ANIP valuation and P/E history · ANIP returns
No forecast, no recommendation. This page describes Ani Pharmaceuticals Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.